HGEN - Humanigen plunges 57% as trial for COVID-19 therapy fails

• The shares of clinical-stage biotech Humanigen, Inc. ( NASDAQ: HGEN ) dropped ~57% in the pre-market Wednesday after the company announced that its experimental antibody Lenzilumab failed in a trial involving hospitalized COVID-19 patients.
• ACTIV-5/BET-B trial was a partnership between Humanigen ( HGEN ) and the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients.
• According to preliminary topline data, trial did not show statistical significance on the primary endpoint.
• However, the results indicated a non-significant trend of a decline in mortality in the overall patient population [HR 0.72]. The researchers found no new safety events related to lenzilumab.
• “…..while the ACTIV-5/BET-B study showed signs of a clinical effect, the benefit demonstrated was not able to confirm the positive results we saw in our Phase 3 LIVE-AIR study,” Chief Executive Cameron Durrant noted.

For further details see: